Clinical trialNCT03317158RecruitingPhase 1/PHASE2Interventional

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

SponsorNoah Hahn, M.D.Enrollment55Bladder CancerUrothelial Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Noah M. Hahn, MD
Hoosier Cancer Research Network
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Bcg Oncology
Phoenix, Arizona, United States
Terminated
Stanford University
Stanford, California, United States
Withdrawn
Rush University Medical Cneter
Chicago, Illinois, United States
Withdrawn
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
Costantine Albany, MDHristos Kaimakliotis, MDNabil Adra, MDRoberto Pili, MD
Recruiting
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Michael A. O'Donnell, MD
Recruiting
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Withdrawn
Washington University School of Medicine
St Louis, Missouri, United States
Zachary Smith, MD
Recruiting
University of Nebraska Medical Center
Omaha, Nebraska, United States
Harshraj Leuva, MD
Recruiting
Columbia University Irving Medical Center
New York, New York, United States
Christopher B. Anderson, MD
Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Active, not recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Daniel Geynisman, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Nov 2017
Primary completion: 31 Dec 2026
Completion: 31 Dec 2027
Last update posted: 15 Apr 2026
Registered enrollment: 55
Registry id: NCT03317158

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.